Table 1 Baseline demographics and disease characteristics of patients by sustained SDAI remission statusa
Characteristic | Patients who achieved sustained SDAI remissiona | Patients who did not achieve sustained SDAI remissiona | ||
|---|---|---|---|---|
Abatacept + MTX (n = 56) | Abatacept placebo + MTX (n = 17) | Abatacept + MTX (n = 395) | Abatacept placebo + MTX (n = 284) | |
Age, years | 44.9 (13.8) | 41.3 (13.1) | 49.5 (12.5) | 49.2 (13.9) |
Female sex, n (%) | 39 (69.6) | 13 (76.5) | 310 (78.5) | 230 (81.0) |
Race, n (%) | ||||
 White | 43 (76.8) | 13 (76.5) | 272 (68.9) | 196 (69.0) |
 Asian | 9 (16.1) | 4 (23.5) | 68 (17.2) | 48 (16.9) |
 Black/African American | 0 | 0 | 20 (5.1) | 16 (5.6) |
 American Indian/Alaska Native | 0 | 0 | 0 | 3 (1.1) |
 Other | 4 (7.1) | 0 | 35 (8.9) | 21 (7.4) |
Geographic region, n (%) | ||||
 North America | 2 (3.6) | 0 | 57 (14.4) | 47 (16.5) |
 South America | 30 (53.6) | 9 (52.9) | 163 (41.3) | 103 (36.3) |
 Asia | 9 (16.1) | 4 (23.5) | 67 (17.0) | 46 (16.2) |
 Europe | 14 (25.0) | 4 (23.5) | 84 (21.3) | 64 (22.5) |
 Rest of world | 1 (1.8) | 0 | 24 (6.1) | 24 (8.5) |
RA disease duration, months | 1.0 (1.2) | 1.2 (1.5) | 1.2 (1.4) | 1.3 (1.4) |
RF positive, n (%) | 53 (94.6) | 14 (82.4) | 367 (92.9) | 265 (93.3) |
Tender joint count (28 joints) | 10.1 (5.1) | 8.6 (4.0) | 13.6 (6.9) | 14.0 (6.8) |
Swollen joint count (28 joints) | 8.1 (4.4) | 7.5 (2.6) | 10.3 (5.8) | 10.9 (5.9) |
CRP, mg/L | 11.4 (14.1) | 9.8 (9.5) | 21.2 (28.2) | 19.6 (22.4) |
Patient Global Assessment of disease activity | 65.2 (19.6) | 52.2 (22.1) | 65.7 (23.1) | 63.4 (24.1) |
Physician Global Assessment of disease activity | 63.1 (16.2) | 47.5 (13.2) | 65.4 (18.8) | 67.2 (19.5) |
SDAI | 32.18 (10.5) | 27.12 (8.1) | 39.1 (14.3) | 40.1 (13.7) |
DAS28 (CRP) | 5.1 (0.8) | 4.8 (0.9) | 5.6 (1.1) | 5.7 (1.0) |
HAQ-DI | 1.4 (0.8) | 1.2 (0.8) | 1.6 (0.7) | 1.6 (0.7) |
Patient assessment of pain (0–100 mm VAS) | 65.9 (18.5) | 54.1 (25.5) | 66.6 (23.1) | 66.1 (22.1) |